COBRE: RIH: THEME A: FETAL PROTEINS & PHENOTYPES IN CANCER: NOVEL HCC VACCINES

COBRE：RIH：主题 A：胎儿蛋白质

• 批准号: 7960507
• 负责人: MAUREEN A CHUNG
• 金额: $ 2.84万
• 依托单位: RHODE ISLAND HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-07-10 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7960507
• 关键词: Alcohol abuse; BCG Vaccine; Cancer Etiology; Cancer Vaccines; Centers of Research Excellence; Computer Retrieval of Information on Scientific Projects Database; Development; Fetal Proteins; Funding; Grant; Institution; Interleukin-2; Liver Cirrhosis; Malignant Neoplasms; Mucin-1 Staining Method; NCI Center for Cancer Research; Patients; Phenotype; Prevention; Primary carcinoma of the liver cells; Rattus; Research; Research Personnel; Resources; Risk; Secondary to; Source; Tumor Antigens; United States National Institutes of Health; Vaccines; Virus Diseases; cancer therapy; design; innovation; mortality; novel; novel vaccines; research and development

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The object of this COBRE project is to design BCG vaccines that target TuAg1 (CD155) and MUC1. Theme A: Significance of Fetal Protein and Phenotypes in Cancer Novel Hepatocellular Vaccines Targeting Rat CD155 and MUC1 This research is focused on the development of novel vaccines for the prevention and/or treatment of cancer. The objective of this project is to develop innovative cancer vaccines that may be useful in the management of patients at risk for, or with ,hepatocellular carcinoma. Hepatocellular carcinoma is a leading cause of cancer mortality worldwide and frequently develops in patients with liver cirrhosis secondary to alcohol abuse or viral infections. Her vaccine uses BCG that have been genetically altered to express interleukin-2 and TuAg1, a tumor associated antigen over-expressed in hepatocellular carcinoma

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 该Cobre项目的目标是设计针对TuAg1(CD155)和MUC1的卡介苗疫苗。主题A：胎儿蛋白和表型在癌症中的意义 针对大鼠CD155和MUC1的新型肝细胞疫苗 这项研究的重点是开发用于预防和/或治疗癌症的新型疫苗。该项目的目标是开发创新的癌症疫苗，这种疫苗可能对肝细胞癌风险患者或合并肝细胞癌的患者的管理有用。 肝细胞癌是世界范围内癌症死亡的主要原因，经常发生在因酗酒或病毒感染而继发的肝硬变患者中。她的疫苗使用的是卡介苗，这种卡介苗已经经过基因改造，可以表达白介素2和肿瘤相关抗原TuAg1，后者是一种在肝细胞癌中过度表达的抗原